comparemela.com

Page 4 - Aaron Sverdlov News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Race Oncology Ltd extends collaborative research program with University of Newcastle for cardio-protective drug Zantrene® in cancer patients

This strategically important collaboration will underpin a cardio-protective Phase 2b clinical trial in cancer patients at high risk of.

Daniel tillettAaron sverdlovDoan ngoRace oncology ltdNational heart foundation future leader fellowshipHunter medical research instituteHunter new england local health districtUniversity of newcastleAssociate professors aaron sverdlovCalvary mater newcastleRising stars

Race Oncology Ltd interim results for Zantrene oncology treatment remarkable , protects heart from cell death during chemotherapy

“Zantrene is the first anti-cancer agent that we have found to exhibit a cardioprotective profile while being synergistically effective as an.

Daniel tillettAaron sverdlovDoan ngoNikki verrillsPhillip lynchRace oncology ltdUniversity of newcastleAssociate professors aaron sverdlovAssociate professor nikki verrillsRace oncologyAcute myeloid leukaemiaThree pillar

Race Oncology Ltd interim results for Zantrene oncology treatment remarkable , protects heart from cell death during chemotherapy

“Zantrene is the first anti-cancer agent that we have found to exhibit a cardioprotective profile while being synergistically effective as an.

Daniel tillettAaron sverdlovDoan ngoNikki verrillsPhillip lynchRace oncology ltdUniversity of newcastleAssociate professors aaron sverdlovAssociate professor nikki verrillsRace oncologyAcute myeloid leukaemiaThree pillar

Race Oncology Ltd targets multiple cancer indications as it advances Zantrene

Clinical stage RNA focused company targeting multiple cancer indications with estimated annual oncology revenues of >US$2.6 billion

United statesDaniel tillettChaim shebaAaron sverdlovDoan ngoXu dong zhangNikki verrillsPhillip lynchRace oncology ltdUniversity of newcastleAcute myeloid leukaemiaAustralian phaseThree pillarProfessor naglerChaim sheba israelProfessor xu dong zhang

New Zantrene Cancer Drug protects the heart from death

Australian biotech and precision oncology company, Race Oncology, has announced breakthrough preclinical research that has found its drug Zantrene® is able to protect heart muscle cells from death while improving the killing of breast cancer cells when used in combination with the anthracycline, doxorubicin. - Health News - eTurboNews | Trends | Travel News

Daniel tillettAaron sverdlovDoan ngoNikki verrillsUniversity of newcastleRace oncologyAssociate professorsAssociate professorChief scientific officer

vimarsana © 2020. All Rights Reserved.